TrialThe Lancet. Oncology2026

Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

Theodore L DeWeese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.